{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:54Z","timestamp":1793771994427,"version":"4.6.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CPX-351 and venetoclax and azacitidine (ven\/aza) are both indicated as initial therapy for acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized comparisons of these regimens, we used retrospective observational data to evaluate various outcomes for patients with newly diagnosed AML receiving either CPX-351 (n = 217) or ven\/aza (n = 439). This study used both a nationwide electronic health record (EHR)-derived de-identified database and the University of Pennsylvania EHR. Our study includes 217 patients who received CPX-351 and 439 who received ven\/aza. Paitents receiving ven\/aza were older, more likely to be treated in the community, and more likely to have a diagnosis of de novo acute myeloid leukemia. Other baseline covariates were not statistically significantly different between the groups. Median overall survival (OS) for all patients was 12 months and did not differ based on therapy (13 months for CPX-351 vs 11 months for ven\/aza; hazard ratio, 0.88; 95% confidence interval, 0.71-1.08; P = .22). OS was similar across multiple sensitivity analyses. Regarding safety outcomes, early mortality was similar (10% vs 13% at 60 days). However, documented infections were higher with CPX-351 as were rates of febrile neutropenia. Hospital length of stay, including any admission before the next cycle of therapy, was more than twice as long for CPX-351. In this large multicenter real-world dataset, there was no statistically significant difference in OS. Prospective randomized studies with careful attention to side effects, quality of life, and impact on transplant outcomes are needed in these populations.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007265","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T21:02:53Z","timestamp":1651698173000},"page":"3997-4005","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-3998","authenticated-orcid":false,"given":"Andrew H.","family":"Matthews","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V.","family":"Babushok","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1312-6748","authenticated-orcid":false,"given":"Ivan P.","family":"Maillard","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Carroll","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"McCurdy","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6413-951X","authenticated-orcid":false,"given":"Vikram R.","family":"Paralkar","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena Jordan","family":"Bruno","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, Epidemiology and Informatics, Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Margolis","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, Epidemiology and Informatics, Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8266","authenticated-orcid":false,"given":"Keith W.","family":"Pratz\u00a0","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"2022070815220609500_B1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"issue":"7","key":"2022070815220609500_B2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol."},{"issue":"12","key":"2022070815220609500_B3","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica."},{"issue":"5","key":"2022070815220609500_B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood."},{"issue":"9","key":"2022070815220609500_B5","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood."},{"issue":"15","key":"2022070815220609500_B6","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer."},{"issue":"26","key":"2022070815220609500_B7","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022070815220609500_B8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"21","key":"2022070815220609500_B9","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2003.03.186","article-title":"Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials","volume":"21","author":"Mengis","year":"2003","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022070815220609500_B10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2141.2008.07561.x","article-title":"Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre","volume":"145","author":"Stevens","year":"2009","journal-title":"Br J Haematol."},{"issue":"2","key":"2022070815220609500_B11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022070815220609500_B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood."},{"issue":"20","key":"2022070815220609500_B13","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv."},{"issue":"24","key":"2022070815220609500_B14","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"2022070815220609500_B15","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"issue":"9596","key":"2022070815220609500_B16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet."},{"key":"2022070815220609500_B17","author":"Birnbaum","year":"2020"},{"key":"2022070815220609500_B18","first-page":"2020.2003.2016.20037143","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv."},{"issue":"8","key":"2022070815220609500_B19","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"issue":"12","key":"2022070815220609500_B20","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol."},{"issue":"10","key":"2022070815220609500_B21","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood."},{"issue":"8","key":"2022070815220609500_B22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1023\/B:EJEP.0000036568.02655.f8","article-title":"Loss to follow-up in cohort studies: how much is too much?","volume":"19","author":"Kristman","year":"2003","journal-title":"Eur J Epidemiol."},{"key":"2022070815220609500_B23","author":"StataCorp","year":"2019"},{"issue":"3","key":"2022070815220609500_B24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11121-007-0070-9","article-title":"How many imputations are really needed? Some practical clarifications of multiple imputation theory","volume":"8","author":"Graham","year":"2007","journal-title":"Prev Sci."},{"issue":"4","key":"2022070815220609500_B25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2010","journal-title":"Stat Med."},{"issue":"1","key":"2022070815220609500_B26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: How should multiple imputation be used?","volume":"28","author":"Leyrat","year":"2017","journal-title":"Stat Methods Med Res."},{"issue":"1","key":"2022070815220609500_B27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1541-0420.2011.01666.x","article-title":"Combining multiple imputation and inverse-probability weighting","volume":"68","author":"Seaman","year":"2011","journal-title":"Biometrics."},{"issue":"12","key":"2022070815220609500_B28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol."},{"issue":"7","key":"2022070815220609500_B29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol."},{"issue":"1","key":"2022070815220609500_B30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"2022070815220609500_B31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J."},{"issue":"10","key":"2022070815220609500_B32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","volume":"10","author":"Guolo","year":"2020","journal-title":"Blood Cancer J."},{"issue":"9","key":"2022070815220609500_B33","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1080\/10428194.2021.1907378","article-title":"Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia","volume":"62","author":"Benitez","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2022070815220609500_B34","doi-asserted-by":"crossref","first-page":"E196","DOI":"10.1002\/ajh.26157","article-title":"Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)","volume":"96","author":"Salhotra","year":"2021","journal-title":"Am J Hematol."},{"key":"2022070815220609500_B35","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2019-130379","article-title":"Hypomethylating agent and venetoclax combination yields comparable outcomes to CPX-351 in newly diagnosed acute myeloid leukemia","volume":"134","author":"Asghari","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3997\/1905993\/advancesadv2022007265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/13\/3997\/1905993\/advancesadv2022007265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T15:23:08Z","timestamp":1657293788000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/13\/3997\/485148\/Real-world-effectiveness-of-CPX-351-vs-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007265","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}